INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Kansas, University of Chicago, Medical College of Wisconsin, Medical College of Wisconsin Cancer Center, University of California, San Francisco, Virginia Commonwealth University Medical Center, Winship Cancer Institute, Summa Akron City Hospital, Massachusetts General Hospital, Cedars-Sinai Medical Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3135600845